Clostridium difficile associated infections: An updated view;Infecciones causadas por clostridium difficile: Una visión actualizada

Revista Chilena de Infectologia

Volumn 29, Issue 4, 2012, Pages 434-445

  Hernández Rocha, Cristian ^a   Naour, Sebastián ^b   Álvarez Lobos, Manuel ^a   Paredes Sabja, Daniel ^b,c  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b UNIVERSIDAD ANDRÉS BELLO   (Chile)

^c OREGON STATE UNIVERSITY   (United States)

Author keywords

Antibiotic associated colitis; C. difficile; Cdai; Pseudomembranous colitis; Spores; Toxic megacolon

Indexed keywords

ANTIINFECTIVE AGENT; VIRULENCE FACTOR;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTION; HUMAN; ISOLATION AND PURIFICATION; PATHOGENICITY; RECURRENT DISEASE; REVIEW; RISK FACTOR;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS; RECURRENCE; RISK FACTORS; VIRULENCE FACTORS;

EID: 84866354679     PISSN: 07161018     EISSN: None     Source Type: Journal    
DOI: 10.4067/S0716-10182012000400011     Document Type: Review

References (136)

1. Deneve C, Janoir C, Poilane I, Fantinato C, Collignon A. New trends in Clostridium diffic ile virulence and pathogenesis. Int J Antimicrob Agents 2009; 33 Suppl 1: S24-8.
2. Zilberberg M D, Shorr A F, Kollef M H. Increase in adult Clostridium difficile-related hospi talizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 2008; 14: 929-31.
3. Herrera P, Cotera A, Fica A, Galdo T, Alvo M. High incidence and complications of Clostridium difficile diarrhea among patients with renal diseases. Rev Med Chile 2003; 131: 397-403.
4. Karas J A, Enoch D A, Aliyu S H. A review of mortality due to Clostridium difficile infectio n. J Infect 2010; 61: 1-8.
5. McFarland L V, Surawicz C M, Greenberg R N, Fekety R, Elmer G W, Moyer K A, et al. A randomize d placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271: 191 3-8.
6. McFarland L V, Elmer G W, Surawicz C M. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97: 1769-75.
7. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocominal Clostridium difficile-associated disease during epidemic caused by a hypervirulent strain in Quebec. Can Med Assoc J 2005; 173: 1037-42.
8. Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366: 1079-84.
9. Bartlett J G. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 2006; 145: 758-64.
10. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009; 7: 526-36.
11. Just I, Selzer J, Wilm M, von Eichel-Streiber C, Mann M, Aktories K. Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature. 1995; 375: 500-3.
12. Jank T, Giesemann T, Aktories K. Rhoglucosylating Clostridium difficile toxins A and B: new insights into structure and function. Glycobiology. 2007; 17: 15R-22R.
13. Paredes-Sabja D, Sarker M R. Germination response of spores of the pathogenic bacterium Clostridium perfringens and Clostridium difficile to cultured human epithelial cells. Anaerobe 2011; 17: 78-84.
14. Paredes-Sabja D, Sarker M R. Adherence of Clostridium difficile spores to Caco-2 cells in culture. J Med Microbiol 2012 May 17 (Epub ahead of print).
15. Planche T, Aghaizu A, Holliman R, Riley P, Poloniecki J, Breathnach A, et al. Diagnosis of Clostridium difficile infection by toxin detection kits: a systematic review. Lancet Infect Dis 2008; 8: 777-84.
16. Schmidt ML, Gilligan PH. Clostridium difficile testing algorithms: what is practical and feasible? Anaerobe 2009; 15: 270-3.
17. Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding DN, et al. A mouse model of Clostridium difficileassociated disease. Gastroenterology 2008; 135: 1984-92.
18. Steele J, Feng H, Parry N, Tzipori S. Piglet models of acute or chronic Clostridium difficile illness. J Infect Dis 2010; 201: 428-34.
19. Sun X, Wang H, Zhang Y, Chen K, Davis B, Feng H. Mouse relapse model of Clostridium difficile infection. Infect Immun 2011; 79: 2856-64.
20. Heap J T, Pennington O J, Cartman S T, Carter G P, Minton NP. The ClosTron: a universal gene knock-out system for the genus Clostridium. J Microbiol Methods 2007; 70: 452-64.
21. Cartman S T, Minton N P. A mariner-based transposon system for in vivo random mutagenesis of Clostridium difficile. Appl Environ Microbiol 2010; 76: 1103-9.
22. Heap J T, Kuehne S A, Ehsaan M, Cartman S T, Cooksley C M, Scott J C, et al. The ClosTron: Mutagenesis in Clostridium refined and streamlined. J Microbiol Methods 2010; 80: 49-55.
23. Gerding D N, Muto C A, Owens R C, Jr. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis 2008; 46 Suppl 1: S43-9.
24. Sorg J A, Sonenshein A L. Bile salts and glycine as co-germinants for Clostridium difficile spores. J Bacteriol. 2008; 190: 2505-12.
25. Wilson K H, Kennedy M J, Fekety F R. Use of sodium taurocholate to enhance spore recovery on a medium selective for Clostridium difficile. J Clin Microbiol 1982; 15: 443-6.
26. Wilson K H. Efficiency of various bile salt preparations for stimulation of Clostridium difficile spore germination. J Clin Microbiol 1983; 18: 1017-9.
27. Sorg J A, Sonenshein A L. Chenodeoxycholate is an inhibitor of Clostridium difficile spore germination. J Bacteriol 2009; 191: 1115-7.
28. Mekhjian H S, Phillips S F, Hofmann A F. Colonic absorption of unconjugated bile acids: perfusion studies in man. Dig Dis Sci 1979; 24: 545-50.
29. Northfield T C, McColl I. Postprandial concentrations of free and conjugated bile acids down the length of the normal human small intestine. Gut 1973; 14: 513-8.
30. Hamilton J P, Xie G, Raufman J P, Hogan S, Griffin T L, Packard C A, et al. Human cecal bile acids: concentration and spectrum. Am J Physiol Gastrointest Liver Physiol 2007; 293: G256-63.
31. Mallonee D H, Hylemon P B. Sequencing and expression of a gene encoding a bile acid transporter from Eubacterium sp. strain VPI 12708. J Bacteriol 1996; 178: 7053-8.
32. Ridlon J M, Kang D J, Hylemon P B. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 2006; 47: 241-59.
33. Sorg J A, Sonenshein A L. Inhibiting the initiation of Clostridium difficile spore germination using analogues of chenodeoxycholic acid, a bile acid. J Bacteriol 2010; 192: 4983-90.
34. Goulding D, Thompson H, Emerson J, Fairweather N F, Dougan G, Douce G R. Distinctive profiles of infection and pathology in hamsters infected with Clostridium difficile strains 630 and B1. Infect Immun 2009; 77: 5478-85.
35. Paredes-Sabja D, Cofré-Araneda G, Pizarro-Guajardo M, Sarker M R. Clostridium difficile spore-macrophage interactions: spore survival. Submitted for publication. 2012.
36. Baines S D, O'Connor R, Saxton K, Freeman J, Wilcox M H. Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model. J Antimicrob Chemother 2009; 63: 520-5.
37. Na X, Kim H, Moyer M P, Pothoulakis C, LaMont J T. gp96 is a human colonocyte plasma membrane binding protein for Clostridium difficile toxin A. Infect Immun 2008; 76: 2862-71.
38. Pothoulakis C, Lamont J T. Microbes and microbial toxins: paradigms for microbialmucosal interactions II. The integrated response of the intestine to Clostridium difficile toxins. Am J Physiol Gastrointest Liver Physiol 2001; 280: G178-83.
39. Kelly C P, Becker S, Linevsky J K, Joshi M A, O'Keane J C, Dickey B F, et al. Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. J Clin Invest 1994; 93: 1257-65.
40. Thelestam M, Chaves-Olarte E. Cytotoxic effects of the Clostridium difficile toxins. Curr Top Microbiol Immunol 2000; 250: 85-96.
41. Keates A C, Castagliuolo I, Qiu B, Nikulasson S, Sengupta A, Pothoulakis C. CGRP upregulation in dorsal root ganglia and ileal mucosa during Clostridium difficile toxin A-induced enteritis. Am J Physiol 1998; 274: G196-202.
42. Pothoulakis C, Castagliuolo I, Leeman S E, Wang C C, Li H, Hoffman B J, et al. Substance P receptor expression in intestinal epithelium in Clostridium difficile toxin A enteritis in rats. Am J Physiol 1998; 275: G68-75.
43. Castagliuolo I, Wang C C, Valenick L, Pasha A, Nikulasson S, Carraway R E, et al. Neurotensin is a proinflammatory neuropeptide in colonic inflammation. J Clin Invest 1999; 103: 843-9.
44. Siffert J C, Baldacini O, Kuhry J G, Wachsmann D, Benabdelmoumene S, Faradji A, et al. Effects of Clostridium difficile toxin B on human monocytes and macrophages: possible relationship with cytoskeletal rearrangement. Infect Immun 1993; 61: 1082-90.
45. Hodges K, Gill R. Infectious diarrhea: Cellular and molecular mechanisms. Gut Microbe 2010; 1: 4-21.
46. Carter G P, Awad M M, Kelly M L, Rood J I, Lyras D. TcdB or not TcdB: a tale of two Clostridium difficile toxins. Future Microbiol 2011; 6: 121-3.
47. Dupuy B, Matamouros S. Regulation of toxin and bacteriocin synthesis in Clostridium species by a new subgroup of RNA polymerase sigmafactors. Res Microbiol. 2006; 157: 201-5.
48. Mani N, Dupuy B. Regulation of toxin synthesis in Clostridium difficile by an alternative RNA polymerase sigma factor. Proc Natl Acad Sci U S A. 2001; 98: 5844-9.
49. Popoff M R, Rubin E J, Gill D M, Boquet P. Actin-specific ADP-ribosyltransferase produced by a Clostridium difficile strain. Infect Immun 1988; 56: 2299-306.
50. Barth H, Aktories K, Popoff M R, Stiles B G. Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteins. Microbiol Mol Biol Rev. 2004; 68: 373-402, table of contents. Review.
51. Kaiser E, Kroll C, Ernst K, Schwan C, Popoff M, Fischer G, et al. Membrane translocation of binary actin-ADP-ribosylating toxins from Clostridium difficile and Clostridium perfringens is facilitated by cyclophilin A and Hsp90. Infect Immun 2011; 79 (10): 3913-21.
52. Geric B, Carman R J, Rupnik M, Genheimer C W, Sambol S P, Lyerly D M, et al. Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters. J Infect Dis 2006; 193: 1143-50.
53. Janvilisri T, Scaria J, Chang Y F. Transcriptional profiling of Clostridium difficile and Caco-2 cells during infection. J Infect Dis 2010; 202: 282-90.
54. Cerquetti M, Molinari A, Sebastianelli A, Diociaiuti M, Petruzzelli R, Capo C, et al. Characterization of surface layer proteins from different Clostridium difficile clinical isolates. Microb Pathog 2000; 28: 363-72.
55. Calabi E, Ward S, Wren B, Paxton T, Panico M, Morris H, et al. Molecular characterization of the surface layer proteins from Clostridium difficile. Mol Microbiol 2001; 40: 1187-99.
56. Takeoka A, Takumi K, Koga T, Kawata T. Purification and characterization of S layer proteins from Clostridium difficile GAI 0714. J Gen Microbiol 1991; 137: 261-7.
57. Sebaihia M, Wren B W, Mullany P, Fairweather N F, Minton N, Stabler R, et al. The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nat Genet 2006; 38: 779-86.
58. Savariau-Lacomme M P, Lebarbier C, Karjalainen T, Collignon A, Janoir C. Transcription and analysis of polymorphism in a cluster of genes encoding surface-associated proteins of Clostridium difficile. J Bacteriol 2003; 185: 4461-70.
59. Ali S, Moore G, Wilson A P. Spread and persistence of Clostridium difficile spores during and after cleaning with sporicidal disinfectants. J Hosp Infect 2011; 79: 97-8.
60. Guerrero D M, Nerandzic M M, Jury L A, Jinno S, Chang S, Donskey C J. Acquisition of spores on gloved hands after contact with the skin of patients with Clostridium difficile infection and with environmental surfaces in their rooms. Am J Infect Control. 2011 Oct 7 (Epub ahead of print).
61. O'Connor J R, Johnson S, Gerding D N. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology. 2009; 136: 1913-24.
62. Pituch H. Clostridium difficile is no longer just a nosocomial infection or an infection of adults. Int J Antimicrob Agents 2009; 33 Suppl 1: S42-5.
63. Limbago B M, Long C M, Thompson A D, Killgore G E, Hannett G E, Havill N L, et al. Clostridium difficile strains from communityassociated infections. J Clin Microbiol 2009; 47: 3004-7.
64. Kutty P K, Woods C W, Sena A C, Benoit S R, Naggie S, Frederick J, et al. Risk factors for and estimated incidence of community-associated Clostridium difficile infection, North Carolina, USA. Emerg Infect Dis 2010; 16: 197-204.
65. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 2009; 58: 403-10.
66. Bauer M P, Goorhuis A, Koster T, Numan- Ruberg S C, Hagen E C, Debast S B, et al. Community-onset Clostridium difficileassociated diarrhoea not associated with antibiotic usage--two case reports with review of the changing epidemiology of Clostridium difficile-associated diarrhoea. Neth J Med 2008; 66: 207-11.
67. Songer G, Anderson M. Clostridium difficile: an important pathogen of food animals. Anaerobe. 2006; 12: 1-4.
68. Songer J G. The emergence of Clostridium difficile as a pathogen of food animals. Anim Health Res Rev 2004; 5: 321-6.
69. Indra A, Lassnig H, Baliko N, Much P, Fiedler A, Huhulescu S, et al. Clostridium difficile: a new zoonotic agent? Wien Klin Wochenschr 2009; 121: 91-5.
70. Songer J G. Clostridia as agents of zoonotic disease. Vet Microbiol 2010; 140: 399-404.
71. Rupnik M. Is Clostridium difficile-associated infection a potentially zoonotic and foodborne disease? Clin Microbiol Infect 2007; 13: 457-9.
72. Rodríguez-Palacios A, Staempfli H, Duffield T, Weese J. Clostridium difficile in retail ground meat, Canada. Emerg Infect Dis 2007; 13: 485-7.
73. Rodríguez-Palacios A, Reid-Smith R J, Staempfli H R, Daignault D, Janecko N, Avery B P, et al. Possible seasonality of Clostridium difficile in retail meat, Canada. Emerg Infect Dis 2009; 15: 802-5.
74. Weese J S, Avery B P, Rousseau J, Reid-Smith R J. Detection and enumeration of Clostridium difficile spores in retail beef and pork. Appl Environ Microbiol 2009; 75: 5009-11.
75. Songer J G, Trinh H T, Killgore G E, Thompson A D, McDonald L C, Limbago BM. Clfostridium difficile in retail meat products, USA, 2007. Emerg Infect Dis 2009; 15: 819-21.
76. Bakri M M, Brown D J, Butcher J P, Sutherland A D. Clostridium difficile in ready-to-eat salads, Scotland. Emerg Infect Dis 2009; 15: 817-8.
77. Janvilisri T, Scaria J, Thompson A D, Nicholson A, Limbago B M, Arroyo L G, et al. Microarray identification of Clostridium difficile core components and divergent regions associated with host origin. J Bacteriol 2009; 191: 3881-91.
78. Spencer R C. The role of antimicrobial agents in the aetiology of Clostridium difficile-associated disease. J Antimicrob Chemother 1998; 41 Suppl C: 21-7.
79. Adams V, Lyras D, Farrow K A, Rood J I. The clostridial mobilisable transposons. Cell Mol Life Sci 2002; 59: 2033-43.
80. Roberts M C, McFarland L V, Mullany P, Mulligan M E. Characterization of the genetic basis of antibiotic resistance in Clostridium difficile. J Antimicrob Chemother 1994; 33: 419-29.
81. Spigaglia P, Carucci V, Barbanti F, Mastrantonio P. ErmB determinants and Tn916- like elements in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother 2005; 49: 2550-3.
82. O'Connor J R, Galang M A, Sambol S P, Hecht D W, Vedantam G, Gerding D N, et al. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother 2008; 52: 2813-7.
83. Ackermann G, Tang Y J, Kueper R, Heisig P, Rodloff A C, Silva J Jr, et al. Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA. Antimicrob Agents Chemother 2001; 45: 2348-53.
84. Dridi L, Tankovic J, Burghoffer B, Barbut F, Petit J C. gyrA and gyrB mutations are implicated in cross-resistance to ciprofloxacin and moxifloxacin in Clostridium difficile. Antimicrob Agents Chemother 2002; 46: 3418-21.
85. Farrow K A, Lyras D, Rood J I. Genomic analysis of the erythromycin resistance element Tn5398 from Clostridium difficile. Microbiology 2001; 147: 2717-28.
86. Larson H E, Borriello S P. Quantitative study of antibiotic-induced susceptibility to Clostridium difficile enterocecitis in hamsters. Antimicrob Agents Chemother 1990; 34: 1348-53.
87. Dzink J, Bartlett J G. In vitro susceptibility of Clostridium difficile isolates from patients with antibiotic-associated diarrhea or colitis. Antimicrob Agents Chemother 1980; 17: 695-8.
88. Bouza E, Muñoz P, Alonso R. Clinical manifestations, treatment and control of infections caused by Clostridium difficile. Clin Microbiol Infect 2005; 11 Suppl 4: 57-64.
89. Loo V G, Bourgault A M, Poirier L, Lamothe F, Michaud S, Turgeon N, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011; 365: 1693-703.
90. Nerandzic M M, Pultz M J, Donskey C J. Examination of potential mechanisms to explain the association between proton pump inhibitors and Clostridium difficile infection. Antimicrob Agents Chemother 2009; 53: 4133-7.
91. Hookman P, Barkin J S. Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol 2009; 15: 1554-80.
92. Scheánchez T H, Brooks J T, Sullivan P S, Juhasz M, Mintz E, Dworkin M S, et al. Bacterial diarrhea in persons with HIV infection, United States, 1992-2002. Clin Infect Dis. 2005; 41: 1621-7.
93. Alvarez M, González R, Briceno I, Cofré C, Labarca J, Vial P, et al. Diagnosis of Clostridium difficile diarrhea: in search of a more efficient clinical focus. Rev Med Chile 2001; 129: 620-5.
94. Tedesco F J, Gordon D, Fortson W C. Approach to patients with multiple relapses of antibioticassociated pseudomembranous colitis. Am J Gastroenterol 1985; 80: 867-8.
95. Lipp M J, Pagovich O E, Rabin D, Min A D, Bernstein B B. Prevalence of diverticulosis in recurrent Clostridium difficile infection. World J Gastroenterol 2010; 16: 345-7.
96. Bartlett J G. Clostridium difficile-associated enteric disease. Curr Infect Dis Rep 2002; 4: 477-83.
97. O'Donoghue C, Kyne L. Update on Clostridium difficile infection. Curr Opin Gastroenterol 2011; 27: 38-47.
98. Bauer M P, Kuijper E J, van Dissel J T. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009; 15: 1067-79.
99. Espino A. Nuevos desafíos en la colitis asociada a Clostridium difficile. Gastroenterol Latinoam. 2009; 20: 105-11.
100. Shen B O, Jiang Z D, Fazio V W, Remzi F H, Rodríguez L, Bennett A E, et al. Clostridium difficile infection in patients with ileal pouchanal anastomosis. Clin Gastroenterol Hepatol 2008; 6: 782-8.
101. Shen B, Remzi F H, Fazio VW. Fulminant Clostridium difficile-associated pouchitis with a fatal outcome. Nat Rev Gastroenterol Hepatol 2009; 6: 492-5.
102. Cohen S H, Gerding D N, Johnson S, Kelly C P, Loo V G, McDonald L C, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-55.
103. Chang T W, Lauermann M, Bartlett J G. Cytotoxicity assay in antibiotic-associated colitis. J Infect Dis 1979; 140: 765-70.
104. Notomi T, Okayama H, Masubuchi H, Yonekawa T, Watanabe K, Amino N, et al. Loop-mediated isothermal amplification of DNA. Nucleic Acids Res 2000; 28: E63.
105. Reller M E, Lema C A, Perl T M, Cai M, Ross T L, Speck K A, et al. Yield of stool culture with isolate toxin testing versus a two-step algorithm including stool toxin testing for detection of toxigenic Clostridium difficile. J Clin Microbiol 2007; 45: 3601-5.
106. Sharp S E, Ruden L O, Pohl J C, Hatcher P A, Jayne L M, Ivie W M. Evaluation of the C. Diff Quik Chek Complete Assay, a new glutamate dehydrogenase and A/B toxin combination lateral flow assay for use in rapid, simple diagnosis of Clostridium difficile disease. J Clin Microbiol 2010; 48: 2082-6.
107. Swindells J, Brenwald N, Reading N, Oppenheim B. Evaluation of diagnostic tests for Clostridium difficile infection. J Clin Microbiol 2010; 48: 606-8.
108. Ticehurst J R, Aird D Z, Dam L M, Borek A P, Hargrove J T, Carroll K C. Effective detection of toxigenic Clostridium difficile by a twostep algorithm including tests for antigen and cytotoxin. J Clin Microbiol 2006; 44: 1145-9.
109. Larson A M, Fung A M, Fang F C. Evaluation of tcdB real-time PCR in a three-step diagnostic algorithm for detection of toxigenic Clostridium difficile. J Clin Microbiol 2010; 48: 124-30.
110. Novak-Weekley S M, Marlowe E M, Miller J M, Cumpio J, Nomura J H, Vance P H, et al. Clostridium difficile testing in the clinical laboratory by use of multiple testing algorithms. J Clin Microbiol. 2010; 48: 889-93.
111. Wilcox M H, Planche T, Fang F C, Gilligan P. What is the current role of algorithmic approaches for diagnosis of Clostridium difficile infection? J Clin Microbiol 2010; 48: 4347-53.
112. Valiquette L, Cossette B, Garant M P, Diab H, Pepin J. Impact of a reduction in the use of highrisk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis 2007; 45 Suppl 2: S112-21.
113. Loo V G, Libman M D, Miller M A, Bourgault A M, Frenette C H, Kelly M, et al. Clostridium difficile: a formidable foe. Can Med Assoc J 2004; 171: 47-8.
114. Tipper D J, Linnett P E. Distribution of peptidoglycan synthetase activities between sporangia and forespores in sporulating cells of Bacillus sphaericus. J Bacteriol 1976; 126: 213-21.
115. Sloan L M, Duresko B J, Gustafson D R, Rosenblatt J E. Comparison of real-time PCR for detection of the tcdC gene with four toxin immunoassays and culture in diagnosis of Clostridium difficile infection. J Clin Microbiol 2008; 46: 1996-2001.
116. Aichinger E, Schleck C D, Harmsen W S, Nyre L M, Patel R. Nonutility of repeat laboratory testing for detection o f Clostridium difficile by use of PCR or enzyme immunoassay. J Clin Microbiol 2008; 46: 3795-7.
117. Gerding D N, Muto C A, Owens R C, Jr. Treatment of Clostridium difficile infection. Clin Infect Dis 2008; 46 Sup pl 1: S32-42.
118. Zar F A, Bakkanagari S R, Moorthi K M, Davis M B. A comparison of vancomycin and metronidazole for the treatment o f Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302-7.
119. Apisarnthanarak A, Razavi B, Mundy L M. Adjunctive intracolonic vancomycin for severe Clostridium difficile col itis: case series and review of the literature. Clin Infect Dis 2002; 35: 690-6.
120. Maroo S, Lamont J T. Recurrent Clostridium difficile. Gastroenterology 2006; 130: 1311-6.
121. Johnson S, Schriever C, Patel U, Patel T, Hecht D W, Gerding D N. Rifaximin redux: treatment of recurrent Clostr idium difficile infections with rifaximin immediately postvancomycin treatment. Anaerobe 2009; 15: 290-1.
122. Garey K W, Ghantoji S S, Shah D N, Habib M, Arora V, Jiang Z D, et al. A randomized, doubleblind, placebo-control led pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother 2011; 66: 2850-5.
123. Butler M, Bliss D, Drekonja D, Filice G, Rector T, MacDonald R, et al. Effectiveness of early diagnosis, prev ention, and treatment of Clostridium difficile infection. Rockville (MD): Agency for Health Research and Quality (US); 2011 Dec. Rep N° 11 (12)-EHC051-EF. AHRQ Comparative Effcetiveness Reviews.
124. Duggan S T. Fidaxomicin: In Clostridium difficile infection. Drugs 2011; 71: 2445-56.
125. Bauer M P, van Dissel J T. Alternative strategies for Clostridium difficile infection. Int J Antimicrob Agents 20 09; 33 Suppl 1: S51-6.
126. Seal D, Borriello S P, Barclay F, Welch A, Piper M, Bonnycastle M. Treatment of relapsing Clostridium difficile d iarrhoea by administration of a non-toxigenic strain. Eur J Clin Microbiol 1987; 6: 51-3.
127. Surawicz C M, McFarland L V, Greenberg R N, Rubin M, Fekety R, Mulligan M E, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000; 31: 1012-7.
128. Sougioultzis S, Kyne L, Drudy D, Keates S, Maroo S, Pothoulakis C, et al. Clostridium difficile toxoid vaccine inrecurrent C. difficileassociated diarrhea. Gastroenterology 2005; 128: 764-70.
129. Giannasca P J, Zhang Z X, Lei W D, Boden J A, Giel M A, Monath T P, et al. Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect Immun 1999; 67: 527-38.
130. Gorbach S L, Chang T W, Goldin B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacill us GG. Lancet 1987; 2: 1519.
131. Lund-Tonnesen S, Berstad A, Schreiner A, Midtvedt T. Clostridium difficile-associated diarrhea treated with homo logous feces. Tidsskr Nor Laegeforen 1998; 118: 1027-30.
132. Mayfield J L, Leet T, Miller J, Mundy L M. Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis 2000; 31: 995-1000.
133. Johnson S, Homann S R, Bettin K M, Quick J N, Clabots C R, Peterson L R, et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebocontrolled trial. Ann Intern Med 1992; 117: 297-302.
134. Carling P, Fung T, Killion A, Terrin N, Barza M. Favorable impact of a multidisciplinary antibiotic management p rogram conducted during 7 years. Infect Control Hosp Epidemiol 2003; 24: 699-706.
135. Best E L, Fawley W N, Parnell P, Wilcox M H. The potential for airborne dispersal of Clostridium difficile from sym ptomatic patients. Clin Infect Dis 2010; 50: 1450-7.
136. Roberts K, Smith CF, Snelling A M, Kerr K G, Banfield K R, Sleigh P A, et al. Aerial dissemination of Clostridium difficile spores. BMC Infect Dis 2008; 8: 7.